Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Non-Current Deffered Revenue (2017 - 2025)

Historic Non-Current Deffered Revenue for vTv Therapeutics (VTVT) over the last 9 years, with Q3 2025 value amounting to $18.7 million.

  • vTv Therapeutics' Non-Current Deffered Revenue changed 0.0% to $18.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.7 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $18.7 million for FY2024, which is 0.0% changed from last year.
  • Per vTv Therapeutics' latest filing, its Non-Current Deffered Revenue stood at $18.7 million for Q3 2025, which was down 0.0% from $18.7 million recorded in Q2 2025.
  • Over the past 5 years, vTv Therapeutics' Non-Current Deffered Revenue peaked at $18.7 million during Q2 2022, and registered a low of $9000.0 during Q2 2021.
  • Over the past 5 years, vTv Therapeutics' median Non-Current Deffered Revenue value was $18.7 million (recorded in 2022), while the average stood at $15.4 million.
  • As far as peak fluctuations go, vTv Therapeutics' Non-Current Deffered Revenue plummeted by 9912.2% in 2021, and later surged by 20733333.33% in 2022.
  • vTv Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $9000.0 in 2021, then skyrocketed by 207333.33% to $18.7 million in 2022, then changed by 0.0% to $18.7 million in 2023, then changed by 0.0% to $18.7 million in 2024, then changed by 0.0% to $18.7 million in 2025.
  • Its last three reported values are $18.7 million in Q3 2025, $18.7 million for Q2 2025, and $18.7 million during Q1 2025.